Human cancer therapeutic targets are classified into three types – phosphatase and tensin homolog (PTEN) (50%), tumor protein p53 (TP53) (8.3%), and other types (41.7%) – using the miRNA entangling target sorter (METS) algorithm in quantum miRNA language and artificial intelligence (MIRAI). Although this data reveals that PTEN is the primary therapeutic target of cancer, the effects of PTEN on cervical and ovarian cancer remain unclear. To elucidate the relationship between PTEN and female genital cancer, the etiology was investigated by METS/MIRAI from a serum biomarker miRNA panel. Information on circulating microRNA (miRNA) in cervical and ovarian cancer sera was extracted from the database. Protein targets of human papilloma virus (HPV) virus miRNAs were predicted by a functional analogy assay. The METS/MIRAI analysis was performed according to the previous computer simulation proceeding. Tumor suppressors, PTEN and TP53, were inhibited in cervical cancer by upregulation of miR-205-5p and miR-25-3p hubs. On the contrary, the miR-205-5p and miR-25-3p hubs have demonstrated anticancer activity through suppression of oncogenic proteins, including immune inflammatory nuclear factor kappa B subunit 1 (NFKB1), as a new immune surveillance system against cervical cancer. Viral hpv-miR-3h was an oncomir of cervical cancer to be able to break the immune surveillance system. PTEN downregulation was also observed in ovarian cancer by upregulation of miR-205-5p or miR-92a-3p hubs. Further, upregulation of the miR-200 family reduced zinc finger E-box binding homeobox 1/2 (ZEB1/2) neoplastic proteins and blocked ovarian carcinogenesis as an immune surveillance system. Thus, the carcinogenesis of cervical and ovarian cancer depended on the balance between the suppression of PTEN and the programmed immune surveillance system. Furthermore, in ovarian cancer, the sponge effect of long noncoding RNA (lncRNA) XIST was observed by suppressing the expression of miR-200 as a game changer that promotes cancer progression. “Quantum miRNA surveillance” could be a new anti-oncogenic immune system under the malignant state of the reproductive organs. The therapeutic target for ovarian cancer was classified as PTEN type, and those for cervical cancer was a mixed type of PTEN and TP53. Carcinogenesis of cervical and ovarian cancers was shown to progress by a balance between blockade of tumor suppressors and quantum miRNA surveillance.